Ventyx Biosciences, Inc.
DelistedCIK 1851194fmd_10VR37Y1JYPHW7NPV7YX30EWJ9Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2025, 21 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Research and development | 6 | 58 | 88 | 176 | 117 |
| Total operating expenses | 7 | 67 | 113 | 208 | 148 |
| Operating income | (7) | (67) | (113) | (208) | (148) |
| Interest and investment income | – | 0 | 5 | 15 | 13 |
| Other non-operating income (expense) | (21) | (17) | 5 | 15 | 13 |
| Income before taxes | – | (84) | (108) | (193) | (135) |
| Net income | (28) | (84) | (108) | (193) | (135) |
| Net income to common shareholders | (28) | (85) | (108) | – | – |